Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $38.04 USD
Change Today +1.39 / 3.79%
Volume 864.2K
MYGN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 1:33 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

320 Wakara Way

Salt Lake City, UT 84108

United States

Phone: 801-584-3600

Fax: 801-584-3640

Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company has developed and plans to develop additional products in six medical specialties, such as oncology, preventive care, urology, dermatology, autoimmune, and neuroscience. Molecular Diagnostic Testing The company’s molecular diagnostic tests are designed to analyze genes, their expression levels and corresponding proteins to assess an individual’s risk for developing disease later in life, diagnose disease, determine a patient’s likelihood of responding to a particular drug, or assess a patient’s risk of disease progression and disease recurrence. The company’s primary molecular diagnostic tests are: myRisk Hereditary Cancer: DNA sequencing test for assessing the risks for hereditary cancers. The company’s myRisk Hereditary Cancer test represents the next generation of its existing hereditary cancer testing franchise, which the company anticipates would eventually replace its current predictive medicine test offerings (BRACAnalysis, BART, Colaris and Colaris AP, and Melaris) with a single test. myRisk Hereditary Cancer is designed to determine a patient’s hereditary cancer risk for breast cancer, ovarian cancer, colon cancer, uterine cancer, melanoma, pancreatic cancer, prostate cancer and gastric cancer. myRisk Hereditary Cancer was initially released through an early access launch that began in 2013. BRACAnalysis: DNA sequencing test for assessing the risk of developing breast and ovarian cancer. The company’s BRACAnalysis test is an analysis of the BRCA1 and BRCA2 genes for assessing a woman’s risk of developing hereditary breast and ovarian cancer. Additionally, BRACAnalysis might be used to assist patients already diagnosed with breast or ovarian cancer and their physicians in determining the appropriate therapeutic interventions to address their disease. BART: DNA sequencing test for hereditary breast and ovarian cancer. The company’s BART test is based on proprietary technology for detecting large genomic rearrangements in the genes involved in hereditary breast and ovarian cancer patients. BRACAnalysis CDx: DNA sequencing test for use as a companion diagnostic with the poly ADP ribose (PARP) inhibitor Lynparza (olaparib) indicated for use in identifying ovarian cancer patients with deleterious or suspected deleterious germline BRCA variants eligible for treatment with Lynparza. Tumor BRACAnalysis CDx: DNA sequencing test designed to be utilized to predict response to DNA damaging agents, such as platinum based chemotherapy agents and poly ADP ribose inhibitors. Tumor BRACAnalysis CDx looks at both germline and somatic mutations in the BRCA1 and BRCA2 genes giving a more complete picture of potential loss of DNA repair ability within the tumor. COLARIS: DNA sequencing test for assessing the risk of colorectal and uterine cancer. The company’s COLARIS test is an analysis of the MLH1, MSH2, MSH6, PMS2, EPCAM, and MYH genes for assessing a person’s risk of developing colorectal and uterine cancer. Colon cancer is a preventable disease if high-risk individuals diligently have colonoscopies and remove any precancerous polyps. COLARIS AP: DNA sequencing test for assessing the risk of colorectal cancer. The company’s COLARIS AP test detects mutations in the APC and MYH genes, which cause a colon polyp-forming syndrome, such as familial adenomatous polyposis (FAP), a more common variation of the syndrome known as attenuated FAP, and the MYH-associated polyposis signature (MAP). Effective preventive measures include colonoscopy and the removal of pre-cancerous polyps and prophylactic surgery. VectraDA: Protein detection test for assessing the disease activity of rheumatoid arthritis (RA). The company’s Vectra DA test is an objective multi-biomarker blood test validated to measure RA disease activity. Vectra DA assesses multiple mechanisms and pathways associated with RA disease activity and integrates the concentrations of 12 serum proteins into a single score reported on a scale of 1 to 100. The test m

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYGN:US $38.04 USD +1.39

MYGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advanced Drainage Systems Inc $28.34 USD 0.00
Alliance HealthCare Services Inc $14.27 USD +0.36
Foundation Medicine Inc $23.03 USD +0.10
Genomic Health Inc $26.05 USD -0.30
RadNet Inc $6.10 USD +0.16
View Industry Companies
 

Industry Analysis

MYGN

Industry Average

Valuation MYGN Industry Range
Price/Earnings 34.9x
Price/Sales 3.6x
Price/Book 3.9x
Price/Cash Flow 32.1x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYRIAD GENETICS INC, please visit www.myriad.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.